• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » GI Dynamics notches German reimbursement win

GI Dynamics notches German reimbursement win

February 1, 2017 By Sarah Faulkner

GI DynamicsGI Dynamics notches German reimbursement win (ASX:GID) said today that its EndoBarrier device won NUB 1 reimbursement status from the German Institute for the Hospital Remuneration System.

This status is the highest of 4 levels, which will bring in full reimbursement for the Lexington, Mass.-based company at the 143 participating hospitals. Payers at these hospitals will be required to cover the gaps in treatment costs for the EndoBarrier procedure, according to GI Dynamics.

“The NUB 1 designation is an important step towards full reimbursement for EndoBarrier in Germany, where there is a significant need for additional therapeutic options for patients with type 2 diabetes and obesity,” president & CEO Scott Schorer said in prepared remarks. “We look forward to continuing our work with clinical teams in Germany to restore healthy blood sugar levels and achieve weight loss in this patient population.”

The company’s EndoBarrier is a minimally invasive therapy for patients with uncontrolled Type II diabetes and obesity. The EndoBarrier liner is a flexible sleeve, which is placed inside the intestine to create a barrier between ingested food and the patient’s intestinal wall.

The device works by affecting the hormones that play a key role in insulin sensitivity, glucose metabolism, satiety and food intake, GI Dynamics said.

In December, the company raised $1.1 million (AU $1.5 million) and launched an impending security purchase plan looking to raise an additional $732,006 (AU $987, 910).

GI Dynamics sold 69.9 million Chess depository interests, representing nearly 1.4 million shares of stock at 16¢ (AU 22¢) per share to investors in Australia “and other certain jurisdictions”.

In November last year, the company released German registry data on its EndoBarrier device, touting significant weight loss and lowered insulin usage among the 234 patients enrolled in the registry.

Data suggested a mean reduction in absolute HbA1c of 1.3%, as well as a reduction of anti-diabetic medication in 78% of patients. Mean injection doses of insulin were reduced by 42%, the company said.

Filed Under: Diabetes, Wall Street Beat, Weight loss Tagged With: GI Dynamics

More recent news

  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy